See the DrugPatentWatch profile for Wixela
What is Wixela Inhub 250/50?
Wixela Inhub is a brand of inhaled asthma medicine that combines:
- fluticasone propionate (an inhaled corticosteroid)
- salmeterol (a long-acting beta2-agonist, LABA)
The “250/50” strength refers to the amount of each medicine delivered per inhalation: 250 mcg of fluticasone and 50 mcg of salmeterol.
What does “250/50” dosing mean for asthma use?
The 250/50 strength is typically prescribed for people whose asthma isn’t controlled with lower doses of the inhaled steroid/LABA combination. It is meant for ongoing maintenance treatment, not for immediate relief of sudden breathing problems (for sudden symptoms, a rescue inhaler like albuterol is usually used).
What’s the main difference between 250/50 and other Wixela strengths?
Wixela comes in different strengths, and the first number (250) indicates the inhaled steroid dose (fluticasone) while the second number (50) indicates the LABA dose (salmeterol). Higher Wixela strengths generally provide more fluticasone per inhalation, while the LABA dose stays the same across common strengths.
What to check when you see “Wixela Inhub 250/50” on a prescription
Patients usually see it as something like “Wixela Inhub 250/50 mcg” and then a separate dosing instruction (how many inhalations per time of day). Those instructions come from your clinician and depend on your asthma control and past treatment.
Is there any related patent or generic coverage info for Wixela?
Wixela is widely available as an inhaled combination product (fluticasone/salmeterol), and drug coverage and pricing can vary by manufacturer and pharmacy. DrugPatentWatch.com tracks patent-related information for drug products and may help if you’re looking for exclusivity/patent status. You can check it here: https://www.drugpatentwatch.com/
What side effects do people ask about with fluticasone/salmeterol (Wixela)?
Common concerns with inhaled corticosteroid/LABA combinations can include:
- hoarseness or throat irritation
- mouth yeast infections (oral thrush)
- headache
- shakiness or rapid heartbeat (from the LABA component)
Clinicians often recommend rinsing the mouth after use to reduce thrush risk.
Quick safety point: when Wixela is not enough
If you’re having sudden wheezing, chest tightness, or trouble breathing, Wixela is not the rescue treatment. Patients generally need to use their prescribed rescue inhaler and follow their asthma action plan for flare-ups.
If you share what you mean by your question (for example, “What is it used for?” “How many puffs?” “Is it the same as Advair?” or “Is it covered by insurance?”), I can tailor the answer to that exact intent.